Initiating and monitoring cholinesterase inhibitor treatment for Alzheimer's disease.
Int J Geriatr Psychiatry. 1999.
PMID: 10340182
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1994 | 2 |
| 1998 | 1 |
| 1999 | 3 |
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 0 |
Search Results
36 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
Primary Palliative Care in Dementia.
Neurotherapeutics. 2022 Jan;19(1):143-151. doi: 10.1007/s13311-021-01171-x. Epub 2022 Jan 26.
Neurotherapeutics. 2022.
PMID: 35080735
Free PMC article.
Review.
Excellent primary palliative care also involves discussion of deprescribing medications of uncertain benefit such as long term use of cholinesterase inhibitors and memantine and being vigilant in the monitoring of pain with its relationship to behavioral dist …
Excellent primary palliative care also involves discussion of deprescribing medications of uncertain benefit such as long term use of cho …
Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs.
J Neurosci Rural Pract. 2023 Oct-Dec;14(4):566-573. doi: 10.25259/JNRP_356_2023. Epub 2023 Oct 7.
J Neurosci Rural Pract. 2023.
PMID: 38059250
Free PMC article.
Review.
Alzheimer's disease (AD), a neurodegenerative disease, is the most common form of amnestic dementia in the geriatric population. ...BPSD mitigators include brexpiprazole, an atypical antipsychotic with a once-daily dosage suited to treat agitation in d …
Alzheimer's disease (AD), a neurodegenerative disease, is the most common form of amnestic dementia in the geria …
A practical algorithm for managing Alzheimer's disease: what, when, and why?
Ann Clin Transl Neurol. 2015 Mar;2(3):307-23. doi: 10.1002/acn3.166. Epub 2015 Jan 23.
Ann Clin Transl Neurol. 2015.
PMID: 25815358
Free PMC article.
Review.
Alzheimer's disease (AD) is the most common form of dementia and its prevalence is increasing. ...Pharmacologic therapy for AD should be initiated upon diagnosis. All of the currently available cholinesterase inhibitors (ChEIs; don …
Alzheimer's disease (AD) is the most common form of dementia and its prevalence is increasing. ...Pharmacologic ther …
Dementia -- Caring, Ethics, Ethnical and Economical Aspects: A Systematic Review [Internet].
Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun. SBU Assessment No. 172.
Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun. SBU Assessment No. 172.
PMID: 28876770
Free Books & Documents.
Review.
But it offers family members the opportunity to obtain some valuable relief. DRUG THERAPIES: Existing studies have not found that treatment with cholinesterase inhibitors (donepezil, galantamine and rivastigmine) affects the progress of mild to moderate Al …
But it offers family members the opportunity to obtain some valuable relief. DRUG THERAPIES: Existing studies have not found that treatme …
Diagnosis, management, and treatment of Alzheimer disease: a guide for the internist.
Arch Intern Med. 1999 Apr 26;159(8):789-98. doi: 10.1001/archinte.159.8.789.
Arch Intern Med. 1999.
PMID: 10219924
Review.
Alzheimer disease (AD) is a diagnosis of inclusion based on patient history, physical examination, neuropsychological testing, and laboratory studies; however, there is no definitive diagnostic test for AD. ...Other cholinesterase inhibitors are in dev …
Alzheimer disease (AD) is a diagnosis of inclusion based on patient history, physical examination, neuropsychological testing, …
Initiating and monitoring cholinesterase inhibitor treatment for Alzheimer's disease.
Int J Geriatr Psychiatry. 1999 Apr;14(4):244-8. doi: 10.1002/(sici)1099-1166(199904)14:4<244::aid-gps917>3.0.co;2-o.
Int J Geriatr Psychiatry. 1999.
PMID: 10340182
The availability of acetylcholinesterase inhibitors for the treatment of Alzheimer's disease raises a number of clinical and ethical questions. ...Instead the primary care physician should refer potentially suitable patients for specialist asses …
The availability of acetylcholinesterase inhibitors for the treatment of Alzheimer's disease raises a num …
The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.
Drugs Aging. 2015 Jul;32(7):537-47. doi: 10.1007/s40266-015-0273-x.
Drugs Aging. 2015.
PMID: 26033268
Review.
Current pharmacological therapy for Alzheimer's disease (AD) includes the cholinesterase inhibitors (ChEIs) donepezil, rivastigmine, and galantamine and the N-methyl D-aspartate receptor antagonist memantine. ...While side effects are gen …
Current pharmacological therapy for Alzheimer's disease (AD) includes the cholinesterase inhibitors …
Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis.
Drugs Aging. 2023 Nov;40(11):953-964. doi: 10.1007/s40266-023-01065-x. Epub 2023 Sep 8.
Drugs Aging. 2023.
PMID: 37682445
Free PMC article.
METHODS: We sought to determine the risk of psychiatric adverse events associated with the use of AChEIs through a systematic review and meta-analysis of double-blind randomized controlled trials involving patients with Alzheimer's dementia and Parkinson's dementia. …
METHODS: We sought to determine the risk of psychiatric adverse events associated with the use of AChEIs through a systematic review and met …
Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease.
J Clin Psychiatry. 1998;59 Suppl 13:23-30.
J Clin Psychiatry. 1998.
PMID: 9771827
Review.
Alzheimer's disease affects multiple domains of human brain function and has neuropsychological, neuropsychiatric, and neurologic manifestations. ...Cholinergic therapies ameliorate behavioral alteration in Alzheimer's disease, and change …
Alzheimer's disease affects multiple domains of human brain function and has neuropsychological, neuropsychiatric, and …
Pharmacological treatment of cognitive deficits in Alzheimer's disease.
Med J Aust. 2001 Sep 17;175(6):324-9. doi: 10.5694/j.1326-5377.2001.tb143593.x.
Med J Aust. 2001.
PMID: 11665948
Review.
Clinical trials and independent reviews support the use of cholinesterase inhibitors for treating the symptoms of patients with mild to moderate Alzheimer's disease (AD). ...Compliance with cholinesterase inhibitor therapy s …
Clinical trials and independent reviews support the use of cholinesterase inhibitors for treating the symptoms of patients wit …
Cite